Amantadine/oseltamivir/ribavirin - Adamas Pharmaceuticals

Drug Profile

Amantadine/oseltamivir/ribavirin - Adamas Pharmaceuticals

Alternative Names: ADS-8902; Amantadine/ribavirine/oseltamivir; Oseltamivir/amantadine/ribavirin; Oseltamivir/ribavirin/amantadine; Ribavirin/amantadine/oseltamivir; Ribavirin/oseltamivir/amantadine

Latest Information Update: 14 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adamas Pharmaceuticals
  • Developer Adamas Pharmaceuticals; National Institutes of Health (USA)
  • Class Acetamides; Adamantanes; Antivirals; Cyclohexenes; Esters; Furans; Organic bridged compounds; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Dopamine receptor agonists; Ion channel modulators; Neuraminidase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Influenza A virus H1N1 subtype; Influenza A virus infections

Most Recent Events

  • 14 Sep 2017 Chemical structure information added
  • 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Canada (PO)
  • 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top